Navigation Links
Biomarker predicts disease recurrence in colorectal cancer
Date:2/17/2009

(PHILADELPHIA) Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.

Detection of the biomarker, guanylyl cyclase 2C (GUCY2C), indicates the presence of occult metastases in lymph nodes that may not have been identified by current cancer staging methods, according to Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Jefferson Medical College of Thomas Jefferson University.

According to Dr. Waldman, who is also the Samuel M.V. Hamilton Professor of Clinical Pharmacology in the Department of Medicine at Jefferson Medical College, colorectal cancer that has metastasized, or spread, to the regional lymph nodes carries a worse prognosis and a higher risk for recurrence. However, these metastases are often missed, and the cancer is understaged.

"One of the unmet needs in colorectal cancer is an accurate staging method to determine how far the disease has spread," said Dr. Waldman, who is also director of the Gastrointestinal Malignancies Program at the Kimmel Cancer Center at Jefferson. "The current standard method, histopathology, is imperfect since it only involves looking at a very small sample of the regional lymph nodes under a microscope. There is no way to know whether occult metastases are present in the rest of the tissue."

Dr. Waldman and his colleagues conducted a prospective, multicenter study of 257 patients with colorectal cancer that had no metastases identified in the lymph nodes (node-negative) according to current standards. They analyzed the lymph nodes for GUCY2C expression using a technique called reverse transcriptase-polymerase chain reaction (RT-PCR). This technique, according to Dr. Waldman, amplifies the sensitivity to detect cancer cells compared to histopathology.

The majority of patients 87.5 percent had lymph nodes that were positive for GUCY2C. Among those patients, 20.9 percent developed recurrent disease. By comparison, only 6.3 percent of the patients whose lymph nodes were negative for GUCY2C developed recurrent disease.

The patients were followed for a median of 24 months for disease recurrence or death. Indeed, patients who expressed GUCY2C had a shorter time to recurrence and a shorter disease-free survival. The prognostic value of the marker persisted even after a multivariate analysis that took other known prognostic factors into account.

According to Dr. Waldman, 20 to 30 percent of patients diagnosed with node-negative colorectal cancer experience disease recurrence within five years. This is approximately the same rate of recurrence as that for some categories of patients diagnosed with node-positive disease. These observations suggest that there are occult metastases in the lymph nodes of node-negative patients at the time of diagnosis. GUCY2C specifically identifies these occult metastases that indicate risk for recurrent disease.

"Beyond predicting disease recurrence, detecting this biomarker could be useful for identifying patients who might benefit from treatment with adjuvant chemotherapy, which is specifically given to patients with node-positive disease," Dr. Waldman said.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Major study on DiagnoCures GCC biomarker published in Jama
2. Researchers ID Biomarker for Fatal Prostate Cancer
3. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
4. MDS Analytical Technologies Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
5. Frost & Sullivan Lauds Toscana Biomarkers Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
6. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
7. Biomarkers improve ischemic stroke prediction
8. Biomarkers: What can they tell us
9. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
10. Common painkillers lower levels of prostate cancer biomarker
11. Biomarkers May Help Spot, Track Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... Mount Sinai Health System today announced the creation of the Medical Modeling ... order 3D models for their cases. Virtual reality, simulation, and 3D printing services ... resource will be the first of its kind catering to the unique patient-specific modeling ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... 06, 2016 , ... After 30 years with The Hearing ... announced her retirement from HASA at the end of 2016. ... individuals and families with hearing and speech services. She has overseen the establishment ...
(Date:12/6/2016)... ... ... It can be argued that people these days spend as much time searching ... their human friends and family. As pets have assumed a bigger role in ... pet products has also increased. , For this reason, America’s Pet Health ...
(Date:12/6/2016)... Atlanta, GA (PRWEB) , ... December 06, 2016 ... ... innovation and the impact of new federal healthcare regulations at the 7th annual ... Galleria Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... N.Y. , Dec. 6, 2016  Licenders is bringing their ... This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is to ... treatment plans are designed to get children right back to class ... are 100% all natural and safe for the whole family," Licenders ...
(Date:12/6/2016)... Dec. 6, 2016  Alopexx Oncology, LLC announced data ... antibody fusion protein (immunocytokine) composed of interleukin-2 and a ... target on B cells as Rituxan and maintains the ... is also involved in tumor targeting, engagement of the ... The results of the study (abstract #95954) were presented ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology: